Bicara Therapeutics BCAX Available for sale investments

Available for sale investments at other companies

AmgenAMGN

——

Arcus BiosciencesRCUS

——

Nuvation BioNUVB

——

Viridian Therapeutics, Inc.VRDN

——

BridgeBio PharmaBBIO

——

Natera, Inc.NTRA

——

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Market cap$1.68B+81.4%

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Bicara Therapeutics's available for sale investments?: Bicara Therapeutics (BCAX) reported available for sale investments of $216.29M in Q1 2026.